28.46
28.46 (0%)
As of Apr 17, 2025
Harmony Biosciences Holdings, Inc. [HRMY]
Source:
Company Overview
Harmony business is cultivating a differentiated neuroscience company, rooted in innovation and driven by a commitment to addressing the unmet needs of patients living with neurological diseases. To date, we have focused on rare neurological diseases with a growing portfolio now spanning sleep/wake, neurobehavioral, and rare epilepsy, and we are harnessing scientific insights and pioneering approaches to advance meaningful treatments that help patients thrive.
| Country | United States |
| Headquarters | plymouth meeting, pennsylvania |
| Phone Number | (484) 539-9800 |
| Industry | |
| CEO | Jeffrey M. Dayno |
| Website | www.harmonybiosciences.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $714.7 |
| Operating Profit | $190.8 |
| Net Income | $145.5 |
| Net Cash | $141.3 |
Profit Ratios
| Gross Margin | $557.9 |
| Operating Margin | 26.7 |
| Profit as % of Revenues | 383.5% |
| Profit as % of Assets | 16.1% |
| Profit as % of Stockholder Equity | 22.1% |
Management Effectiveness
| Return on Equity | 22.1% |
| Return on Assets | 14.6% |
| Turnover Ratio | 79% |
| EBITA | $190.8 |
Balance Sheet and Cash Flow Measures
| Total Assets | $999.2 |
| Total Liabilities | $340 |
| Operating Cash Flow | $219.8 |
| Investing Cash Flow | $-67.5 |
| Financing Cash Flow | $-11 |
